3 Income Stocks to Buy for August 29th

Genmab A/S (GMAB) reported 19% YoY revenue growth and a 56% increase in operating profit in Q2 2025, driven by royalties and strong sales of McKinley and Tivdak. The company has a robust pipeline and is expanding commercial efforts for Epkinly and Tivdak globally. Genmab aims to become a fully integrated biotech powerhouse by 2030, leveraging its KYSO antibody platform and partnerships with large pharmaceutical companies.

Genmab A/S (GMAB) has reported significant financial growth in Q2 2025, with a 19% year-over-year (YoY) increase in revenue and a 56% rise in operating profit. The company attributed this growth to strong sales of McKinley and Tivdak, as well as royalties from its pipeline [1].

Genmab's robust pipeline, particularly its KYSO® platform, has been a key driver of its recent success. The company's antibody-drug conjugates (ADCs) have shown promising results in various clinical trials. For instance, Rinatabart sesutecan (Rina-S®), an ADC targeting advanced endometrial cancer, received a Breakthrough Therapy Designation from the FDA, demonstrating a 50% response rate in trials [2].

The company's expansion efforts for Epkinly and Tivdak globally have also contributed to its financial performance. Genmab aims to become a fully integrated biotech powerhouse by 2030, leveraging its KYSO antibody platform and partnerships with large pharmaceutical companies [1].

Genmab's recent successes in the biotech sector, including the FDA Breakthrough Therapy Designation for Rina-S, have positioned the company as a leader in the development of innovative cancer treatments. The company's ability to translate its pipeline into commercial wins, as demonstrated by its prior success with Darzalex, suggests that Genmab is well-positioned for continued growth.

References:
[1] https://stockanalysis.com/stocks/gmab/revenue/
[2] https://www.ainvest.com/news/genmab-rina-game-changer-endometrial-cancer-catalyst-shareholder-2508/